# An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

> **NCT00774930** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 115 (actual)

## Conditions studied

- Carcinoid Syndrome

## Interventions

- **DRUG:** Lanreotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00774930
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2013-05
- **Final completion:** 2015-12
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00774930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00774930, "An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00774930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*